These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209 [TBL] [Abstract][Full Text] [Related]
6. Rapid emergence of Veziris N; Bernard C; Guglielmetti L; Le Du D; Marigot-Outtandy D; Jaspard M; Caumes E; Lerat I; Rioux C; Yazdanpanah Y; Tiotiu A; Lemaitre N; Brossier F; Jarlier V; Robert J; Sougakoff W; Aubry A; ; Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28182568 [No Abstract] [Full Text] [Related]
8. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. Bloemberg GV; Keller PM; Stucki D; Trauner A; Borrell S; Latshang T; Coscolla M; Rothe T; Hömke R; Ritter C; Feldmann J; Schulthess B; Gagneux S; Böttger EC N Engl J Med; 2015 Nov; 373(20):1986-8. PubMed ID: 26559594 [TBL] [Abstract][Full Text] [Related]
9. Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment. de Vos M; Ley SD; Wiggins KB; Derendinger B; Dippenaar A; Grobbelaar M; Reuter A; Dolby T; Burns S; Schito M; Engelthaler DM; Metcalfe J; Theron G; van Rie A; Posey J; Warren R; Cox H N Engl J Med; 2019 May; 380(22):2178-2180. PubMed ID: 31141643 [No Abstract] [Full Text] [Related]
10. Multidrug-resistant tuberculosis and bedaquiline. Salfinger M; Somoskövi A N Engl J Med; 2014 Dec; 371(25):2435-6. PubMed ID: 25517715 [No Abstract] [Full Text] [Related]
11. Multidrug-resistant tuberculosis and bedaquiline. Diacon AH; Lounis N; Dannemann B N Engl J Med; 2014 Dec; 371(25):2436. PubMed ID: 25517714 [No Abstract] [Full Text] [Related]
12. Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline. Furin J; Diacon AH; Andries K Int J Tuberc Lung Dis; 2017 Jan; 21(1):4-5. PubMed ID: 28157457 [No Abstract] [Full Text] [Related]
13. New World Health Organization Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared? Kranzer K; Kalsdorf B; Heyckendorf J; Andres S; Merker M; Hofmann-Thiel S; Bloemberg GV; Hoffmann H; Niemann S; Lange C; Maurer FP Am J Respir Crit Care Med; 2019 Aug; 200(4):514-515. PubMed ID: 31026398 [No Abstract] [Full Text] [Related]
14. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Ismail NA; Omar SV; Moultrie H; Bhyat Z; Conradie F; Enwerem M; Ferreira H; Hughes J; Joseph L; Kock Y; Letsaolo V; Maartens G; Meintjes G; Ngcamu D; Okozi N; Padanilam X; Reuter A; Romero R; Schaaf S; Te Riele J; Variava E; van der Meulen M; Ismail F; Ndjeka N Lancet Infect Dis; 2022 Apr; 22(4):496-506. PubMed ID: 34780706 [TBL] [Abstract][Full Text] [Related]
16. FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis. Cox E; Laessig K N Engl J Med; 2014 Aug; 371(8):689-91. PubMed ID: 25140952 [No Abstract] [Full Text] [Related]
17. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Somoskovi A; Bruderer V; Hömke R; Bloemberg GV; Böttger EC Eur Respir J; 2015 Feb; 45(2):554-7. PubMed ID: 25359333 [No Abstract] [Full Text] [Related]
18. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270 [TBL] [Abstract][Full Text] [Related]
20. Current issues with the use of bedaquiline. Kakkar AK; Dahiya N Ann Pharmacother; 2014 May; 48(5):666. PubMed ID: 24519480 [No Abstract] [Full Text] [Related] [Next] [New Search]